Tag «GlaxoSmithKline»

TAFENOQUINE, タフェノキン

It’s only fair to share… Tafenoquine タフェノキン N-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl]pentane-1,4-diamine 1,4-Pentanediamine, N4-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]-8-quinolinyl]- 106635-80-7 [RN] 262P8GS9L9 7835 N4-{2,6-Dimethoxy-4-methyl-5-[3-(trifluormethyl)phenoxy]-8-chinolinyl}-1,4-pentandiamin WR-238605, WR 238605, cas no 106635-80-7, Tafenoquine succinate, Etaquine, SB-252263, WR-238605 N(4)-(2,6-Dimethoxy-4-methyl-5-((3-trifluoromethyl)phenoxy)-8-quinolinyl)-1,4-pentanediamine Molecular Formula: C24H28F3N3O3 Molecular Weight: 463.49263 Medicines for Malaria Venture Walter Reed Army Institute (Originator) PATENT  US 4617394 Synonyms Etaquine[5] WR 238605 [5] SB-252263 New Drug Application (NDA): 210795 Company: GLAXOSMITHKLINE FDA approved on July 20, 2018 FDA …

REMOGLIFLOZIN ETABONATE

It’s only fair to share… REMOGLIFLOZIN ETABONATE 5-methyl-4-[4-(1-methylethoxy)benzyl]-1-(1-methylethyl)-1H-pyrazol-3-yl 6-O-(ethoxycarbonyl)-β-D-glucopyranoside, ethyl [(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[5-methyl-1-propan-2-yl-4-[(4-propan-2-yloxyphenyl)methyl]pyrazol-3-yl]oxy-oxan-2-yl]methyl carbonate  https://clinicaltrials.gov/show/NCT02537470   UNII:TR0QT6QSUL CAS 442201-24-3 189075  BHV-091009  GSK-189075  GSK-189075A  KGT-1681  BHV Pharma  Kissei (Originator)  , GlaxoSmithKline Remogliflozin etabonate Phase II A SGLT-2 antagonist potentially for the treatment of type 2 diabetes, non-alcoholic steatohepatitis (NASH), obesity. GSK-189075; GSK-189075A Molecular FormulaC26H38N2O9 Average mass522.588 Remogliflozin etabonate (INN/USAN)[1] …